WO2017194903A3 - Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune - Google Patents
Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune Download PDFInfo
- Publication number
- WO2017194903A3 WO2017194903A3 PCT/FR2017/051165 FR2017051165W WO2017194903A3 WO 2017194903 A3 WO2017194903 A3 WO 2017194903A3 FR 2017051165 W FR2017051165 W FR 2017051165W WO 2017194903 A3 WO2017194903 A3 WO 2017194903A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- viral particle
- cells involved
- rna transfer
- viral rnas
- integrase
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title 1
- 102100034347 Integrase Human genes 0.000 abstract 4
- 108020000999 Viral RNA Proteins 0.000 abstract 3
- 101710170658 Endogenous retrovirus group K member 10 Gag polyprotein Proteins 0.000 abstract 2
- 101710186314 Endogenous retrovirus group K member 21 Gag polyprotein Proteins 0.000 abstract 2
- 101710162093 Endogenous retrovirus group K member 24 Gag polyprotein Proteins 0.000 abstract 2
- 101710094596 Endogenous retrovirus group K member 8 Gag polyprotein Proteins 0.000 abstract 2
- 101710177443 Endogenous retrovirus group K member 9 Gag polyprotein Proteins 0.000 abstract 2
- 101710177291 Gag polyprotein Proteins 0.000 abstract 2
- 101710203526 Integrase Proteins 0.000 abstract 2
- 108010061833 Integrases Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 102100034349 Integrase Human genes 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017263138A AU2017263138B2 (en) | 2016-05-13 | 2017-05-12 | Viral particle for RNA transfer, especially into cells involved in immune response |
CA3023788A CA3023788A1 (fr) | 2016-05-13 | 2017-05-12 | Particule virale pour le transfert d'arns, notamment dans les cellules impliquees dans la reponse immune |
EP17730842.6A EP3454889A2 (fr) | 2016-05-13 | 2017-05-12 | Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune |
CN201780043718.0A CN109562150A (zh) | 2016-05-13 | 2017-05-12 | 用于将rna转移到尤其参与免疫应答的细胞中的病毒颗粒 |
US16/301,354 US11371059B2 (en) | 2016-05-13 | 2017-05-12 | Viral particle for the transfer of RNAs, especially into cells involved in immune response |
JP2018559309A JP6916209B2 (ja) | 2016-05-13 | 2017-05-12 | 特に免疫応答に関与する細胞への、rnaの転移のためのウイルス粒子 |
SG11201810014UA SG11201810014UA (en) | 2016-05-13 | 2017-05-12 | Viral particle for rna transfer, especially into cells involved in immune response |
IL262944A IL262944A (en) | 2016-05-13 | 2018-11-12 | A viral particle for RNA transfer, especially to cells involved in the immune response |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1654333A FR3051197B1 (fr) | 2016-05-13 | 2016-05-13 | Particule virale pour le transfert d'arns dans les cellules impliquees dans la reponse immune |
FR1654333 | 2016-05-13 | ||
FR1752819 | 2017-03-31 | ||
FR1752819 | 2017-03-31 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2017194903A2 WO2017194903A2 (fr) | 2017-11-16 |
WO2017194903A3 true WO2017194903A3 (fr) | 2018-01-25 |
WO2017194903A8 WO2017194903A8 (fr) | 2018-12-27 |
Family
ID=59070996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2017/051165 WO2017194903A2 (fr) | 2016-05-13 | 2017-05-12 | Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune |
Country Status (9)
Country | Link |
---|---|
US (1) | US11371059B2 (fr) |
EP (1) | EP3454889A2 (fr) |
JP (1) | JP6916209B2 (fr) |
CN (1) | CN109562150A (fr) |
AU (1) | AU2017263138B2 (fr) |
CA (1) | CA3023788A1 (fr) |
IL (1) | IL262944A (fr) |
SG (1) | SG11201810014UA (fr) |
WO (1) | WO2017194903A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2986051C (fr) * | 2015-05-15 | 2023-09-26 | Vectalys | Particule retrovirale comportant au moins deux arn non viraux encapsides |
US20210129135A1 (en) * | 2019-11-01 | 2021-05-06 | Nicholas Crabtree | Hourglass shaped blood fractionation tube and system |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0526210D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Vectors |
JP6212039B2 (ja) | 2011-07-27 | 2017-10-11 | ブクタリ | 真核細胞の形質導入に有用なウイルスベースのベクター組成物 |
AU2013207962B2 (en) * | 2012-01-12 | 2017-07-20 | Unm Rainforest Innovations | Immunogenic HPV L2-containing VLPs and related compositions and methods |
WO2016049258A2 (fr) * | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Criblage fonctionnel avec systèmes crisp-cas fonctionnels optimisés |
-
2017
- 2017-05-12 CA CA3023788A patent/CA3023788A1/fr active Pending
- 2017-05-12 EP EP17730842.6A patent/EP3454889A2/fr active Pending
- 2017-05-12 AU AU2017263138A patent/AU2017263138B2/en active Active
- 2017-05-12 SG SG11201810014UA patent/SG11201810014UA/en unknown
- 2017-05-12 WO PCT/FR2017/051165 patent/WO2017194903A2/fr unknown
- 2017-05-12 CN CN201780043718.0A patent/CN109562150A/zh active Pending
- 2017-05-12 US US16/301,354 patent/US11371059B2/en active Active
- 2017-05-12 JP JP2018559309A patent/JP6916209B2/ja active Active
-
2018
- 2018-11-12 IL IL262944A patent/IL262944A/en unknown
Non-Patent Citations (4)
Title |
---|
ANNE PREL ET AL: "Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, vol. 2, 21 October 2015 (2015-10-21), pages 15039, XP055254802, DOI: 10.1038/mtm.2015.39 * |
KATHERINE H. CARRUTHERS ET AL: "Fat Grafting as a Vehicle for the Delivery of Recombinant Adenoassociated Viral Vectors to Achieve Gene Modification of Muscle Flaps", ANNALS OF PLASTIC SURGERY., vol. 70, no. 6, 1 June 2013 (2013-06-01), US, pages 726 - 731, XP055353454, ISSN: 0148-7043, DOI: 10.1097/SAP.0b013e3182414add * |
MICHAEL R. WILLIAMS ET AL: "A Retroviral CRISPR-Cas9 System for Cellular Autism-Associated Phenotype Discovery in Developing Neurons", SCIENTIFIC REPORTS, vol. 6, 10 May 2016 (2016-05-10), pages 25611, XP055352201, DOI: 10.1038/srep25611 * |
PASCALE BOUILLÉ ET AL: "Transient Non-Viral RNA Delivery Mediated by a Lentiviral Particle", MOLECULAR THERAPY, vol. 24, no. S1, 4 May 2016 (2016-05-04), pages S215, XP055354331 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017194903A8 (fr) | 2018-12-27 |
IL262944A (en) | 2018-12-31 |
AU2017263138B2 (en) | 2022-08-25 |
US20190203228A1 (en) | 2019-07-04 |
JP6916209B2 (ja) | 2021-08-11 |
AU2017263138A1 (en) | 2019-01-03 |
SG11201810014UA (en) | 2018-12-28 |
US11371059B2 (en) | 2022-06-28 |
CN109562150A (zh) | 2019-04-02 |
EP3454889A2 (fr) | 2019-03-20 |
WO2017194903A2 (fr) | 2017-11-16 |
JP2019514413A (ja) | 2019-06-06 |
CA3023788A1 (fr) | 2017-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
CY1124518T1 (el) | Μεταλλαγες πρωτεϊνης φακελου hiv που σταθεροποιουν το τριμερες | |
CL2021002741A1 (es) | Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de lachnospiraceae bacterium nd2006; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
WO2016196975A8 (fr) | Anticorps neutralisants dirigés contre la protéine d'enveloppe (env) du vih-1 et leur utilisation | |
WO2019173692A3 (fr) | Anticorps anti-cd73 et leurs procédés d'utilisation | |
WO2018106615A3 (fr) | Compositions et méthodes d'activation d'expression génique | |
EP3950941A3 (fr) | Variants polypeptidiques de la dnase | |
WO2017178653A3 (fr) | Nouveaux anticorps anti-sirpa et leurs applications thérapeutiques | |
SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
WO2017079479A8 (fr) | Anticorps neutralisants dirigés contre la protéine gp41 du vih-1 et leur utilisation | |
JP2017153484A5 (fr) | ||
MX2018007237A (es) | Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus. | |
WO2017066764A3 (fr) | Modification de la région n-terminale des protéines de capsides pour améliorer les propriétés des virus adéno-associés | |
WO2016154003A8 (fr) | Anticorps neutralisants dirigés contre gp120 et utilisation de ceux-ci | |
EP4043031A3 (fr) | Constructions à base d'antigènes du virus zika | |
RU2018132044A (ru) | Антитела против тау | |
MX2020012765A (es) | Métodos y compuestos de ácido nucleico modificado con lípidos. | |
EP4339615A3 (fr) | Anticorps anti-pd-1 | |
WO2017214462A3 (fr) | Anticorps anti-cd98 et conjugués anticorps-médicament | |
WO2017194902A3 (fr) | Particule pour l'encapsidation d'un système d'ingénierie du génome | |
CA3009928A1 (fr) | Vaccin contre le virus de l'encephalite equine base sur un virus modifie de la vaccine ankara (mva) recombinant | |
WO2012018907A3 (fr) | Polypeptides pour traitement et/ou limitation d'infection par la grippe | |
MX2017008096A (es) | Pestivirus. | |
WO2017152146A3 (fr) | Compositions et procédés pour induire des anticorps du vih-1 | |
WO2015112558A3 (fr) | Peptides, dispositifs et procédés pour la détection d'anticorps d'anaplasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3023788 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018559309 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17730842 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2017730842 Country of ref document: EP Effective date: 20181213 |
|
ENP | Entry into the national phase |
Ref document number: 2017263138 Country of ref document: AU Date of ref document: 20170512 Kind code of ref document: A |